Search Results | Blood | American Society of Hematology

1-20 of 738

Sort by

Sort Order Select

Journal Articles

VEXAS syndrome

Peter C. Grayson, Bhavisha A. Patel, Neal S. Young

Blood (2021) 137 (26): 3591–3594.

DOI: https://doi.org/10.1182/blood.2021011455

Published: 2021

Journal Articles

Plasmablasts derive from CD23 – activated B cells after the extinction of IL-4/STAT6 signaling and IRF4 induction

Amandine Pignarre, Fabrice Chatonnet, Gersende Caron, Marion Haas, Fabienne Desmots, Thierry Fest

Blood (2021) 137 (9): 1166–1180.

DOI: https://doi.org/10.1182/blood.2020005083

Published: 2021

Includes: Supplemental data

Journal Articles

LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells

Tomoyasu Jo, Momoko Nishikori, Yasunori Kogure, Hiroshi Arima, Katsuhiro Sasaki, Yoshiteru Sasaki, Tomoko Nakagawa, Fumie Iwai, Shuji Momose, Aki Shiraishi, Hiroshi Kiyonari, Noritaka Kagaya, Tetsuo Onuki, Kazuo Shin-ya, Minoru Yoshida, Keisuke Kataoka, Seishi Ogawa, Kazuhiro Iwai, Akifumi Takaori-Kondo

Blood (2020) 136 (6): 684–697.

DOI: https://doi.org/10.1182/blood.2019002654

Published: 2020

Includes: Supplemental data

Journal Articles

A master erythroid regulator gets its own GPS

Lily Jun-shen Huang, James J. Bieker

Blood (2020) 135 (25): 2209–2210.

DOI: https://doi.org/10.1182/blood.2020005882

Published: 2020

Journal Articles

Wdr26 regulates nuclear condensation in developing erythroblasts

Ru Zhen, Chingyee Moo, Zhenzhen Zhao, Mengying Chen, He Feng, Xiaojun Zheng, Liang Zhang, Jiahai Shi, Caiyong Chen

Blood (2020) 135 (3): 208–219.

DOI: https://doi.org/10.1182/blood.2019002165

Published: 2020

Includes: Supplemental data

Journal Articles

Bioavailable Dual-Protein Degraders of CK1α and Transcriptional Kinase CDK9 As Potential Therapeutics for Hematological Malignancies

Leah Fung, PhD, Aparajita Hoskote Chourasia, PhD, Eduardo Torres, MSc, Imelda Lam, BSc, Paul Erdman, MSc, David Hecht, PhD, Robert Sullivan, PhD, Brooke McElwee, BSc, Normand Richard, MSc, Avanthika Venkatachalam, MSc, Irit Snir-Alkalay, PhD, Kyle WH Chan, PhD, Frank Mercurio, PhD, Yinon Ben-Neriah, MD PhD, David I Stirling, PhD

Blood (2019) 134 (Supplement_1): 4643.

DOI: https://doi.org/10.1182/blood-2019-131834

Published: 2019

Journal Articles

Hydroxyurea Reverses Dysfunctional Ubiquitin-Proteasomal System in Sickle CELL Disease and Suppresses Posttranslational Alterations in Hemoglobin and CELL Membranes

Swee Lay Thein, DSc, MBBS, Arun S Shet, MD, Michael Brad Strader, PhD, Fanato Meng, PhD, Michael Heaven, PhD, Jana Sirsendu, PhD, Abdu Alayash, PhD

Blood (2019) 134 (Supplement_1): 4822.

DOI: https://doi.org/10.1182/blood-2019-122840

Published: 2019

Journal Articles

A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)

Sarit Assouline, MD, Amitkumar Mehta, MD, Paolo F Caimi, MD, Bingxia Wang, PhD, Chirag Patel, Mi-Sook Kim, Dennis Huszar, Allison J Berger, PhD, Sharon Friedlander, Alejandro Gomez-Pinillos, Igor Proscurshim

Blood (2019) 134 (Supplement_1): 1593.

DOI: https://doi.org/10.1182/blood-2019-128773

Published: 2019

Journal Articles

Elucidating the Mechanism of Action of CC-90009, a Novel Cereblon E3 Ligase Modulator, in AML Via Genome-Wide CRISPR Screen

Gang Lu, Christine Surka, Chin-Chun Lu, In Sock Jang, PhD, Kai Wang, PhD, Mark Rolfe, PhD

Blood (2019) 134 (Supplement_1): 405.

DOI: https://doi.org/10.1182/blood-2019-125492

Published: 2019

Journal Articles

IRF4 Is Reciprocally Dysregulated Via NF-Κb-Dependent Expression and Loss-of-Function Mutations in Multiple Myeloma

Yun Dai, MD, Yue Sun, MS, Shaji K. Kumar, MD, Wei Wu, MD, Fengyan Jin, MD PhD

Blood (2019) 134 (Supplement_1): 687.

DOI: https://doi.org/10.1182/blood-2019-132051

Published: 2019

Journal Articles

TRIP13 Modulates Protein Deubiquitination to Promote Myeloma Progression

Can Li, MD, Reinaldo Franqui-Machin, Jiliang Xia, PhD, Gregory S. Thomas, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Fangping Chen, MD PhD, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2019) 134 (Supplement_1): 854.

DOI: https://doi.org/10.1182/blood-2019-123818

Published: 2019

Journal Articles

Innate Immune Signaling Suppresses Acute Leukemia By Modifying MYC Oncogenic Activity

Tomoya Muto, MD PhD, Maria Guillamot, PhD, Jing Fang, MD PhD, Luna Zea Redondo, MS, Kwangmin Choi, PhD, Yixiao Gong, MSc, Callum S Walker, MSc, Kathleen Hueneman, Lyndsey C Bolanos, BSc, Laura Barreyro, PhD, Lynn Lee, MD, Kenneth D Greis, PhD, Alireza Khodadadi-Jamayran, M.Sc., Amaia Lujambio, PhD, Scott W. Lowe, PhD, Iannis Aifantis, PhD, Daniel T. Starczynowski, PhD

Blood (2019) 134 (Supplement_1): 727.

DOI: https://doi.org/10.1182/blood-2019-121423

Published: 2019

Journal Articles

Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors

Max Jan, MD PhD, Ana Castano, MD, Amanda Walker, BA, Andrew A Guirguis, MD PhD, Jessica A Gasser, PhD, Amanda A Bouffard, Mikolaj Slabicki, PhD, Alexander Tepper, Daniel E Grinshpun, Taeyoon Kyung, PhD, Quinlan Sievers, MD PhD, Michael E Birnbaum, PhD, Marcela V Maus, MD PhD, Benjamin L. Ebert, MD PhD

Blood (2019) 134 (Supplement_1): 866.

DOI: https://doi.org/10.1182/blood-2019-124210

Published: 2019

Journal Articles

Integrated Systems Level Examination of Proteasome Inhibitor Stress Recovery in Myeloma Cells Reveals Druggable Vulnerabilities Linked to Multiple Metabolic Processes

Paula Saavedra-Garcia, PhD, Hibah A Al-Sadah, MSc, Lucy Penfold, PhD, Xiaobei Xiong, MRes, Elena Lopez-Jimenez, PhD, Katarzyna Parzych, PhD, Valentina S Caputo, Kevin Blighe, PhD, Martin F. Kaiser, Paolo Piazza, PhD, Vesela Encheva, PhD, Ambrosius P Snijders, PhD, Hector C Keun, DPhil, Diego Oyarzun, PhD, Denise Thiel, MSc, Zijing Liu, PhD, Mauricio Barahona, PhD, Holger W Auner, MD PhD

Blood (2019) 134 (Supplement_1): 1818.

DOI: https://doi.org/10.1182/blood-2019-121549

Published: 2019

Journal Articles

Lenalidomide Induction and Maintenance Maximizes Outcome for Newly Diagnosed Transplant Eligible Myeloma Patients Irrespective of Risk Status: Long-Term Follow-up of the Myeloma XI Trial

Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, David Cairns, MSc, PhD, John R Jones, MD, Bhuvan Kishore, MB BS, MRCP, FRCPath, Mamta Garg, MD FRCP, FRCPath, Cathy Williams, MD MRCP, FRCPath, Kamaraj Karunanithi, MD FRCPath, Jindriska Lindsay, MD, MRCP, FRCPath, Nigel H. Russell, MD, Matthew Jenner, MBBS, MRCP, FRCPath, Gordon Cook, MB ChB, PhD FRCP(Glas), FRCPath, Mark T Drayson, MB ChB, PhD FRCPath, Roger G. Owen, MD, Walter M Gregory, PhD, Martin F. Kaiser, Faith E. Davies, MD, Gareth Morgan, MDPhDFRCP

Blood (2019) 134 (Supplement_1): 1910.

DOI: https://doi.org/10.1182/blood-2019-126160

Published: 2019

Journal Articles

Pharmacologic Inhibition of SUMO-Activating Enzyme (SAE) with TAK-981 Augments Interferon Signaling and Regulates T Cell Differentiation in Ex Vivo studies of Chronic Lymphocytic Leukemia (CLL)

Vi Lam, Scott R Best, BS, Nur Bruss, BS, Tingting Liu, Taylor Hashiguchi Rowland, BS, Dennis Huszar, PhD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 1760.

DOI: https://doi.org/10.1182/blood-2019-127539

Published: 2019

Journal Articles

The Transcriptome of Immunomodulator-Resistant Multiple Myeloma

Moritz Binder, MDMPH, S. Vincent Rajkumar, MD, Martha Q. Lacy, MD, Jessica L. Haug, Angela Dispenzieri, MD, Kimberly J. Henderson, Teresa K. Kimlinger, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 1772.

DOI: https://doi.org/10.1182/blood-2019-123407

Published: 2019

Journal Articles

TNF-α Confers Resistance of Myeloma Cells to IMiDs through TRAF2 Degradation

Jiye Liu, PhD, Teru Hideshima, MD PhD, Lijie Xing, MD, Kenneth Wen, BS, Yu-Tzu Tai, PhD, Yong Cang, PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 1809.

DOI: https://doi.org/10.1182/blood-2019-123141

Published: 2019

Journal Articles

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Mario Scarpa, PhD, Prerna Singh, MS, Shivani Kapoor, MS, Jonelle K. Lee, MS, Sandrine Niyongere, MD, Goutham Narla, MD PhD, Danilo Perrotti, MD PhD, Maria R. Baer, MD

Blood (2019) 134 (Supplement_1): 1276.

DOI: https://doi.org/10.1182/blood-2019-129011

Published: 2019

Journal Articles

Direct Phosphorylation and Stabilization of MYC By Aurora B Kinase Promotes T Cell Leukemogenesis

Hudan Liu, PhD, Jue Jiang, PhD, Jingchao Wang, PhD, Ming Yue, PhD, Hui Feng, MD PhD, Guoliang Qing, PhD

Blood (2019) 134 (Supplement_1): 732.

DOI: https://doi.org/10.1182/blood-2019-130112

Published: 2019

NARROW

VEXAS syndrome

Plasmablasts derive from CD23 – activated B cells after the extinction of IL-4/STAT6 signaling and IRF4 induction

LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells

A master erythroid regulator gets its own GPS

Wdr26 regulates nuclear condensation in developing erythroblasts

Bioavailable Dual-Protein Degraders of CK1α and Transcriptional Kinase CDK9 As Potential Therapeutics for Hematological Malignancies

Hydroxyurea Reverses Dysfunctional Ubiquitin-Proteasomal System in Sickle CELL Disease and Suppresses Posttranslational Alterations in Hemoglobin and CELL Membranes

A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)

Elucidating the Mechanism of Action of CC-90009, a Novel Cereblon E3 Ligase Modulator, in AML Via Genome-Wide CRISPR Screen

IRF4 Is Reciprocally Dysregulated Via NF-Κb-Dependent Expression and Loss-of-Function Mutations in Multiple Myeloma

TRIP13 Modulates Protein Deubiquitination to Promote Myeloma Progression

Innate Immune Signaling Suppresses Acute Leukemia By Modifying MYC Oncogenic Activity

Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors

Integrated Systems Level Examination of Proteasome Inhibitor Stress Recovery in Myeloma Cells Reveals Druggable Vulnerabilities Linked to Multiple Metabolic Processes

Lenalidomide Induction and Maintenance Maximizes Outcome for Newly Diagnosed Transplant Eligible Myeloma Patients Irrespective of Risk Status: Long-Term Follow-up of the Myeloma XI Trial

Pharmacologic Inhibition of SUMO-Activating Enzyme (SAE) with TAK-981 Augments Interferon Signaling and Regulates T Cell Differentiation in Ex Vivo studies of Chronic Lymphocytic Leukemia (CLL)

The Transcriptome of Immunomodulator-Resistant Multiple Myeloma

TNF-α Confers Resistance of Myeloma Cells to IMiDs through TRAF2 Degradation

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Direct Phosphorylation and Stabilization of MYC By Aurora B Kinase Promotes T Cell Leukemogenesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only